



HAL
open science

Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France

Christine Larsen, Vanina Bousquet, Elisabeth Delarocque-Astagneau, Corinne Pioche, Françoise Roudot-Thoraval, Jean-Claude Desenclos

► **To cite this version:**

Christine Larsen, Vanina Bousquet, Elisabeth Delarocque-Astagneau, Corinne Pioche, Françoise Roudot-Thoraval, et al.. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. *Journal of Medical Virology*, 2010, 82 (10), pp.1647. 10.1002/jmv.21850 . hal-00599778

HAL Id: hal-00599778

<https://hal.science/hal-00599778>

Submitted on 11 Jun 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France

Journal:	<i>Journal of Medical Virology</i>
Manuscript ID:	JMV-09-1672.R2
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	13-Apr-2010
Complete List of Authors:	Larsen, Christine; Institut de veille sanitaire, maladies infectieuses Bousquet, Vanina; Institut de veille sanitaire, maladies infectieuses Delarocque-Astagneau, Elisabeth; Institut Pasteur, Epidemiologie des maladies émergentes; Institut de veille sanitaire, maladies infectieuses Pioche, Corinne; Institut de veille sanitaire, maladies infectieuses Roudot-Thoraval, Françoise; Hôpital Henri-Mondor AP-HP, Santé Publique Desenclos, Jean-Claude; Institut de veille sanitaire, maladies infectieuses
Keywords:	alcohol , cirrhosis, drug users, HCV genotype 3, HIV



1
2
3 **Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug**
4 **users in France**
5
6

7 Christine Larsen¹, Vanina Bousquet¹, Elisabeth Delarocque-Astagneau^{1,2}, Corinne Pioche¹, Françoise
8 Roudot-Thoraval³, the HCV surveillance steering committee, the HCV surveillance group and Jean-
9 Claude Desenclos¹
10
11

- 12
13
14 1. Institut de veille sanitaire (InVS), Saint-Maurice, France;
15
16 2. Institut Pasteur, Unité d'épidémiologie des maladies émergentes, Paris, France
17
18 3. Centre hospitalier universitaire, APHP-Henri Mondor, Créteil, France
19

20 **The Hepatitis C surveillance steering committee (France)**
21

22 P. Couzigou (Bordeaux), P. Marcellin (Clichy), F. Roudot-Thoraval (Créteil), P. Hillon (Dijon),
23
24 JP. Zarski (Grenoble), JP. Bronowicki (Nancy), E. Delarocque-Astagneau (Paris), C. Sylvain
25
26 (Poitiers), D. Guyader (Rennes), O. Gorla (Rouen).
27
28

29 **The Hepatitis C surveillance group (France)**
30

31 D. Capron (Amiens); P. Cales, I. Hubert-Fouchard (Angers); V. Di Martino (Besançon); J.
32
33 Foucher (Bordeaux); C. Guillemard (Caen); A. Abergel (Clermont-Ferrand); MP. Ripault
34
35 (Clichy); D. Dhumeaux (Créteil); A. Minello (Dijon); A. Edouard (Fort de France); MN. Hilleret
36
37 (Grenoble); V. Canva (Lille), V. Loustaud-Rati (Limoges); P. Pradat, C. Trepo (Lyon); JJ. Raabe
38
39 (Metz); D. Larrey (Montpellier); J. Gournay (Nantes); E. Marine-Barjoan, A. Tran (Nice); X.
40
41 Causse (Orléans); B. Nalpas, S. Pol (Paris); G. Thieffin (Reims); H. Danielou (Rennes); K.
42
43 Barange (Toulouse); L. D'Alteroche, EH. Metman (Tours).
44
45

46 The contributions of the first three authors are equal.
47

48 **Shortened title:** HCV genotype 3 and cirrhosis in drug users
49

50 **Correspondance to:**
51

52 C. Larsen
53

54 Institut de veille sanitaire, Département des maladies infectieuses
55

56 12 rue du Val d'Osne, 94415 Saint-Maurice cedex, France,
57

58 Email : c.larsen@invs.sante.fr
59
60

Abstract

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 Although risk factors for cirrhosis in chronic hepatitis C virus (HCV) infection have been identified,
3 the role of HCV-genotype 3 remains controversial, and limited data are available in drug users. The
4 aim of the study was to assess risk factors for severe liver disease (cirrhosis/hepatocellular carcinoma)
5 in HCV-infected drug users between 2001 and 2007 in France.

6 Patients who reported drug use and who had been referred for HCV infection to hepatology centres
7 from a national surveillance system were identified. The severity of liver disease was assessed
8 clinically and histologically (Metavir score). Factors associated with severe liver disease were analysed
9 after estimating missing values by multiple imputation.

10 Of the 4065 drug users naive to anti-HCV treatment who were referred to the 26 participating centres,
11 8.0% had severe liver disease, 25.7% were infected with HCV-genotype 3. Factors associated
12 independently with an increased risk of severe liver disease were HCV-genotype 3 (adjusted odds
13 ratio, multiple imputation, (aOR_{MI}) = 1.6, [95%CI: 1.2-2.1]), HIV infection (aOR_{MI} = 1.8, [1.2-2.8]),
14 male sex (aOR_{MI} = 2.0, [1.4-2.8]), age over 40 years (aOR_{MI} = 2.1, [1.6-2.9]), history of excessive
15 alcohol consumption (aOR_{MI} = 2.8, [2.1-3.7]) and duration of infection ≥ 18 years (aOR_{MI} = 2.9, [2.0-
16 4.3]).

17 This analysis shows that HCV-genotype 3 is associated with severe liver disease in drug users,
18 independently of age, sex, duration of infection, alcohol consumption and co-infection with HIV.
19 These results are in favour of earlier treatment for drug users infected with HCV-genotype 3 and
20 confirm the need for concomitant care for excessive alcohol consumption.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3

Keywords: alcohol, cirrhosis, drug users, HCV genotype 3, HIV.

For Peer Review

1 **Introduction**

2 In France, the prevalence of anti-HCV in injecting drug users ranges from 55% to 60% [Jauffret-
3 Roustide et al., 2009; Meffre et al., 2010]. In addition, injecting drug users accounted for more than
4 two thirds of the patients co-infected with HIV and HCV [Larsen et al., 2008].

5 Factors associated with progression of liver fibrosis have been well established, and are related to host
6 factors (age at contamination, male sex), comorbidities (co-infection with HIV, heavy alcohol
7 consumption), metabolic conditions (obesity, steatosis, diabetes mellitus) and duration of infection
8 [Mallat et al., 2008; Massard et al., 2006]. Furthermore, co-infection with HIV and a history of
9 excessive alcohol consumption are linked to death at an earlier age in patients infected chronically
10 with HCV as shown in a recent study on mortality related to chronic hepatitis C in France [Marcellin
11 et al., 2008]. Viral induced steatosis linked to HCV genotype 3 has also emerged as a cofactor for
12 progression of liver fibrosis in patients infected with HCV [Rubbia-Brandt et al., 2004]. HCV
13 genotype 3 is also the most frequent genotype found among drug users infected with HCV in France,
14 accounting for more than one third [Payan et al., 2005]. Excessive alcohol consumption is common in
15 this population, too [Campbell et al., 2006]. However, limited data are available on factors associated
16 with progression to liver fibrosis in former or current injecting drug users infected by HCV.

17 In addition, with new antiviral treatment options and efficacy, recommendations on antiviral treatment
18 of drug users infected with HCV have been expanded in France [Dhumeaux et al., 2003] since the
19 2002 consensus conference on treatment of HCV infection.

20 In France, a surveillance system was set up to monitor changes over time of the epidemiological and
21 clinical characteristics of patients infected with HCV at the first referral to hepatology reference
22 centres; nearly 3900 cases of chronic hepatitis C, of whom 35% acknowledged drug use, have been
23 recorded each year since 2001 by this system. The aim of the present study was to assess risk factors
24 associated with severe liver disease in patients infected with HCV who had reported drug use using
25 the data collected by this surveillance system.

26 **Methods**

27 Study population and inclusion criteria

1
2
3 1 Details of the methods have been described previously [Delarocque-Astagneau et al., 2005]. Briefly,
4
5 2 this surveillance system based on voluntary participation of 26 of the 30 existing hepatology reference
6
7 3 centres was set up in 2000 to monitor changes over time of the epidemiological and clinical
8
9 4 characteristics of patients infected with HCV at the time of their first referral. Hepatology reference
10
11 5 centres are located in University hospitals throughout France. To be included, a case was defined as a
12
13 6 patient with anti-HCV antibodies who was referred (first contact as an in- or out-patient) to any
14
15 7 participating reference centre. Patients can be referred by their general practitioner, by a specialist or
16
17 8 by self-referral. Patients included in the analysis were those who reported having injected or snorted
18
19 9 drugs at least once in their lifetime. To ascertain the first referral, patients with no prior histological
20
21 10 evaluation of their liver disease at referral were selected for the analysis. The surveillance system
22
23 11 obtained ethical approval from the French data protection authority (CNIL).
24
25

26 27 Data collection

28
29 13 A standardized notification form was used in all centres to collect data routinely, including risk
30
31 14 factors for HCV transmission, the last HCV negative test (if available), date and the reasons for
32
33 15 anti-HCV testing, HCV RNA serum status, HCV genotype, co-infections with HIV (anti-HIV
34
35 16 serostatus) and hepatitis B virus (hepatitis B surface antigen serostatus), history of excessive alcohol
36
37 17 consumption defined as more than 210g of pure ethanol per week for women and 280g for men, and
38
39 18 the number of years with excessive consumption. The severity of liver disease was assessed either by
40
41 19 liver biopsy (Metavir scores [Bedossa and Poynard, 1996]) and/or by clinical evaluation including
42
43 20 clinical examination, biochemical tests and imaging (mainly abdominal ultrasound). The clinical
44
45 21 evaluation was graded as follows: repeated normal ALT values defined as ALT levels below the
46
47 22 upper limit of normal at three consecutive tests within six months, chronic hepatitis C, cirrhosis
48
49 23 (compensated or not) and hepatocellular carcinoma. Cirrhosis at clinical evaluation was defined by
50
51 24 the fibrosis Metavir score F4 when a liver biopsy was carried out or by the association of clinical
52
53 25 signs, laboratory findings and ultrasound images used by all participating centres [Schuppan and
54
55 26 Afdhal, 2008]. The diagnostic criteria used for hepatocellular carcinoma were those established
56
57 27 during the Barcelona-2000 EASL Conference [Bruix et al., 2001]).
58
59
60

1
2
3 1 The form was modified in 2004 to include data on non-invasive assessment of liver fibrosis and on
4
5 2 antiviral therapy.

6
7 3 HCV genotyping was carried out by the referral laboratories of the participating centres. Most of these
8
9 4 laboratories were involved in the French ANRS panel quality control study in 2000 [Lefrere et al.,
10
11 5 2004] and the same standardized genotyping assays (Inno LiPA assay) or other methods (sequencing,
12
13 6 primer-specific PCR) during the study period were used.

14
15
16 7 The database was checked regularly for duplicate reporting in and between participating reference
17
18 8 centres.

19
20 9 The suspected year of HCV infection was defined by the year of the last HCV negative test performed
21
22 10 during the drug-use period or year of first drug injection. Time from the suspected year of infection to
23
24 11 the year of referral to the reference centre was used as a surrogate of the duration of HCV infection.

25
26 12 The median duration of infection was used to create a qualitative variable (≥ 18 years; < 18 years) in
27
28 13 the univariate and multivariate analysis.

29
30 14 Patients included in the analysis were drug users with HCV RNA in the serum who were naive to
31
32 15 anti-HCV treatment.

33
34 16 The outcome of severe liver disease was defined as cirrhosis (compensated or not) or hepatocellular
35
36 17 carcinoma at the first referral, based on the clinical assessment.

37
38
39 18 Statistical analysis

40 41 42 19 Factors associated with severe liver disease

43
44 20 Univariate analysis was carried out to assess the characteristics associated with severe liver disease at
45
46 21 clinical evaluation. Variables with p values < 0.2 in univariate analysis were entered into the
47
48 22 multivariate analysis. STATA® 9.2 statistical package was used for the analysis (Stata Corporation,
49
50 23 College Station, Texas, USA).

51
52 24 First, the general approach for multivariate analysis was used including only patients who had no
53
54 25 missing data in any of the variables (complete case analysis). However, six out of the eight variables
55
56 26 included in the multivariate model comprised 10% to 27% of missing values resulting in a loss of
57
58 27 power and precision, complication in data handling and analysis and potentially biased odds ratios
59
60 28 (OR) due to differences between the observed and unobserved data [Little and Rubin, 2002].

1
2
3 1 Therefore, missing values were estimated from the observed values using multiple imputation
4
5 2 (imputation by chained equations, ice procedure STATA® 9.2) [Royston, 2007]. Several complete
6
7 3 data sets (m=30) were created. Each data set was analysed separately, and the results were combined
8
9 4 to obtain the odds ratios [Little & Rubin, 2002]. The sensitivity of the odds ratios to departures from
10
11 5 the assumed missing mechanism was tested for three variables (alcohol consumption, co-infection
12
13 6 with HIV and HCV genotype 3) using a weighting approach developed by Carpenter *et al.* [Carpenter
14
15 7 *et al.*, 2007].
16
17
18
19
20

21 9 **Results**

22
23 10 Of the 5004 drug users who were referred for HCV infection between 2001 and 2007 and who were
24
25 11 naive to anti-HCV treatment, 4236 were HCV RNA positive and were included in the analysis. The
26
27 12 remaining 768 had either a negative (n = 455) or an unspecified (n = 313) result for HCV RNA.
28
29
30
31

32 14 Characteristics of the study population

33
34 15 Of the 4236 patients positive for HCV RNA, 77% were male; the median age was 39 years and the
35
36 16 median estimated duration of HCV infection was 18 years (Table I). Co-infections with HBV and
37
38 17 HIV were diagnosed in 2% and 6%, respectively. A history of excessive alcohol consumption was
39
40 18 reported for 43 %. Among the 1154 patients who reported previous heavy drinking in the past with an
41
42 19 available duration of excessive consumption, 67% had drunk heavily for more than five years. HCV
43
44 20 genotypes were mainly genotype 1 (36%) and 3 (25%), the distribution of HCV genotypes remained
45
46 21 stable over the study period.
47
48

49 22 A liver biopsy was carried out in 53.6% of the drug users included in 2001-2003 and in 27.1% of
50
51 23 those included in 2004-2007. In the latter period, 29.2% had an evaluation of fibrosis by non-invasive
52
53 24 methods only.
54

55 25 A clinical evaluation of liver disease was available for 4065 (96%) patients with HCV RNA, and
56
57 26 severe liver disease was diagnosed in 8% of the patients. Cirrhosis was diagnosed in 301 patients and
58
59 27 hepatocellular carcinoma in 10 patients. Of these 311 patients, 236 (76%) had an available HCV
60

1 genotyping result: HCV genotypes 1 and 3 were found in 48% and 42%, respectively. Of the 164
2 patients with severe liver disease at clinical evaluation who underwent a liver biopsy, the Metavir
3 score F4 was diagnosed for 94% including three out of the four patients with hepatocellular carcinoma
4 (F3 for the remaining patient).

5 In univariate analysis the following variables were associated with a severe liver disease at referral
6 (Table II): inclusion after 2003, male sex, age >40 years at referral, estimated duration of infection
7 ≥ 18 years, history of excessive alcohol intake, co-infection with HIV and HCV genotype 3. Time
8 between the first HCV positive test and referral was not significant.

9 In both the complete-case and the multiple imputation (MI) analyses, the independent factors
10 associated with severe liver disease at clinical evaluation were male sex (adjusted OR_{MI} (aOR_{MI}): 2.0;
11 95% CI, 1.4-2.8), age > 40 years at referral (aOR_{MI} : 2.1; 95% CI, 1.6-2.9), duration of HCV infection
12 ≥ 18 years (aOR_{MI} : 2.9; 95% CI, 2.0-4.3), history of excessive alcohol consumption (aOR_{MI} : 2.8; 95%
13 CI, 2.1-3.7) and HCV genotype 3 (aOR_{MI} : 1.6; 95% CI, 1.2-2.1) (Table III). In the multiple
14 imputation analysis, co-infection with HIV (aOR_{MI} : 1.8; 95% CI, 1.2-2.8) was associated significantly
15 with severe liver disease. No significant interactions were found.

16 The univariate analysis for the factors associated with the F4 Metavir score, limited to the patients
17 who had a liver biopsy (n=1725), showed similar results although the 95% confidence intervals were
18 wider. However, co-infections with HIV and HBV were not significant statistically ($p > 0.25$; data not
19 shown).

21 Discussion

22 This multi-site study documents factors associated with severe liver disease in a large group of
23 patients infected with HCV who reported drug use. The findings confirm the role of excessive alcohol
24 consumption and co-infection with HIV and suggest that HCV genotype 3 is associated with an
25 increased risk of severe liver disease independently of age, sex, duration of infection and excessive
26 alcohol consumption. To our knowledge this is the first study to address the risk factors of severe liver
27 disease in a population of drug users infected with HCV at first referral.

1
2
3 1 Clinical studies have demonstrated a significant association between HCV genotype 3 infection and
4
5 2 the presence of steatosis [Cross et al., 2009; Hui et al., 2002; Rubbia-Brandt et al., 2004]. In patients
6
7 3 infected with HCV genotype 3, fat accumulation in the liver is correlated with the level of HCV
8
9 4 replication [Adinolfi et al., 2001] and disappears following successful antiviral therapy [Castera et al.,
10
11 5 2004]. Although there have been several studies providing evidence for the influence of steatosis on
12
13 6 the progression of fibrosis regardless of the HCV genotype [Cross et al., 2009; Fartoux et al., 2005;
14
15 7 Hu et al., 2004] or in patients infected with HCV genotype 3 [Castera et al., 2003; Castera et al., 2004;
16
17 8 Rubbia-Brandt et al., 2004], the issue remains controversial. Indeed, other studies failed to show any
18
19 9 association between steatosis and liver fibrosis [Asselah et al., 2003; Perumalswami et al., 2006;
20
21 10 Ryder et al., 2004], including one study on a large cohort of patients infected with HCV
22
23 11 [Perumalswami et al., 2006]. However, the comparability of the studies is questionable, as there were
24
25 12 differences in the study populations and the risk factors studied. Furthermore, another study showed
26
27 13 that steatosis had no association with fibrosis in patients infected with HCV genotype 3 [Bugianesi et
28
29 14 al., 2006] suggesting other causes for the progression of fibrosis such as insulin resistance or viral
30
31 15 induced liver inflammation.
32
33
34
35 16 Numerous studies have shown that a past or present history of excessive alcohol consumption was
36
37 17 associated with more rapid progression to fibrosis [Tolstrup et al., 2009; Westin et al., 2002]. As
38
39 18 expected in this particular population of patients who reported drug use, cirrhosis at the time of first
40
41 19 referral was associated strongly with excessive alcohol consumption in the past. The definition of
42
43 20 excessive alcohol consumption used in this study corresponds to more than 30g/day for women and
44
45 21 40g/day for men compared with 50g/day for both sexes in many other studies. Of those who
46
47 22 acknowledged excessive alcohol consumption in the past, more than half reported that the period
48
49 23 lasted at least five years, allowing the development of fibrosis. In addition, more than one third of the
50
51 24 patients who reported excessive alcohol consumption in the past, acknowledged current excessive
52
53 25 consumption. This is consistent with the results reported by Campbell *et al.* [Campbell et al., 2006],
54
55 26 who found that in a population of drug users infected with HCV, knowledge about the detrimental
56
57 27 effects of alcohol consumption related to HCV infection did not appear to influence alcohol use.
58
59
60

1
2
3 1 The analysis of the mortality data in the Swiss hepatitis C cohort showed recently that mortality was
4
5 2 increased for individuals who reported drinking more than 40g alcohol per day. HCV genotype 3 was
6
7 3 associated also with a higher mortality although it did not remain significant in the multivariate
8
9 4 analysis [Prasad et al., 2009].

10 5 HIV infection is known to modify the natural history of HCV by accelerating the rate of progression
11
12 6 of fibrosis and the development of advanced fibrosis both before [Poynard et al., 2003] and since
13
14 7 [Thein et al., 2008] the highly active antiretroviral therapy era. Interestingly, a study has shown
15
16 8 advanced liver fibrosis to be associated with HCV genotype 3 in a population of patients co-infected
17
18 9 with HIV and HCV [Barreiro et al., 2006]. Surprisingly, in the study by Barreiro *et al.* [2006], neither
19
20 10 past nor current excessive alcohol consumption remained associated significantly with advanced liver
21
22 11 fibrosis. However, the assessment of liver fibrosis in this study was based on a non-invasive method
23
24 12 (elastometry) only.

25 13 Among the limitations of the present study is its cross-sectional design. Indeed, it is difficult to use
26
27 14 cross-sectional data to estimate longitudinal parameters. However, although collected at the same time
28
29 15 as the outcome of interest (severe liver disease), most of the variables assessed in this study reflect
30
31 16 exposures that occurred prior to the outcome. Therefore, this study could be considered as a
32
33 17 retrospective cohort, which is less subject to bias than a purely cross-sectional study [Rothman and
34
35 18 Greenland, 1998]. Others factors shown to be associated with progression of fibrosis were not
36
37 19 collected, such as daily cannabis smoking [Hezode et al., 2005] and insulin resistance related to the
38
39 20 patient characteristics such as obesity and type 2 diabetes mellitus, and to the virus [Cua et al., 2008;
40
41 21 Moucari et al., 2008; Petta et al., 2008]. However, Moucari *et al.* [2008] provided evidence that
42
43 22 insulin resistance was associated with HCV genotypes 1 and 4 in contrast to patients with HCV
44
45 23 genotypes 2 and 3. This lower rate of insulin resistance in patients with HCV genotype 3 was shown
46
47 24 also in another study [Hui et al., 2003]. The validity of the method used in the present study for
48
49 25 assessing the severity of liver disease could be called into question since it was not based on
50
51 26 histology. However, the classification used for clinical evaluation of the liver disease is likely to be
52
53 27 homogeneous within the participating reference centres. Furthermore, as the indication for liver
54
55 28 biopsy may be related to certain risk factors or the intention to begin a course of antiviral therapy, the

1
2
3 1 use of the clinical stage for assessment of severe liver disease appeared more suited to the purpose of
4
5 2 the study objectives. Also, the proportion of patients managed in a reference centre who had a liver
6
7 3 biopsy decreased dramatically from 45% in 2001 to 18% in 2006 [Delarocque-Astagneau et al.,
8
9 4 2009]. Indeed, since 2002, physicians in France have been treating patients infected with HCV
10
11 5 genotypes 2 and 3 or with HIV co-infection without performing a liver biopsy, in accordance with the
12
13 6 2002 French recommendations on HCV treatment [Dhumeaux et al., 2003]. The univariate analysis of
14
15 7 the factors associated with the F4 Metavir score limited to patients who had a liver biopsy showed
16
17 8 similar results, but the 95% confidence intervals were wider and co-infection with HIV was not
18
19 9 significant statistically.

20
21
22
23 10 The present analysis was confronted with missing values as it was based on surveillance data. In order
24
25 11 to keep all cases in the analysis, a multiple imputation method was applied to the data. Multiple
26
27 12 imputation is a well established method for the analysis of data sets with missing values. As the
28
29 13 multivariate analysis will include all cases, multiple imputation provides consistency in results [Little
30
31 14 & Rubin, 2002]. Thus, the association between HCV genotype 3 and severe liver disease found in the
32
33 15 complete case analysis was reinforced by the multiple imputation analysis. Also, HIV infection was
34
35 16 associated significantly with severe liver disease after multiple imputation analysis. In addition, the
36
37 17 sensitivity analysis performed on HCV genotype 3, co-infection with HIV and alcohol consumption
38
39 18 allowed to be confident of the robustness of the estimations [Carpenter et al., 2007][data not shown].
40
41 19 A recent analysis of the data from the Swiss hepatitis C cohort found HCV genotype 3 as a factor
42
43 20 associated with progression of liver fibrosis, which reinforced the validity of the results [Bochud et
44
45 21 al., 2009].

46
47
48
49 22 These results suggest that in patients infected chronically with HCV who reported drug use, early
50
51 23 therapeutic intervention should be recommended for those patients who are infected with HCV
52
53 24 genotype 3 and who acknowledge excessive alcohol consumption in the past, since progression to
54
55 25 cirrhosis may be more rapid. Therefore, integrated treatment of HCV and alcohol addiction is
56
57 26 essential. Thus, collaboration between healthcare providers who specialize in the management of
58
59 27 addictions and those who specialize in the management of HCV infection should be promoted.

28 **Acknowledgments**

1
2
3 1 The authors thank the clinicians and patients from all the participating hepatology reference centres
4
5 2 and Dr. Elisabeth Couturier for her critical reviews of the manuscript.
6

7
8 3 **Conflicts of interest:** none
9

10 4 **Financial support:** This work was done within the surveillance activities of the Institut de veille
11
12 5 sanitaire that is funded by the French Ministry of Health.
13

14 6 V. Bousquet is funded by a PhD grant from the Agence Nationale de Recherches sur le Sida et les
15
16 7 hépatites virales (ANRS).
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

References

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1
2
3 Adinolfi LE, Utili R, Andreana A, Tripodi MF, Marracino M, Gambardella M, Giordano M,
4 Ruggiero G. 2001. Serum HCV RNA levels correlate with histological liver damage and
5 concur with steatosis in progression of chronic hepatitis C. *Dig Dis Sci* 46: 1677-1683.
- 6 Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, Daikha H, Vidaud
7 D, Martinot M, Vidaud M, Degott C, Valla D, Marcellin P. 2003. Liver fibrosis is not
8 associated with steatosis but with necroinflammation in French patients with chronic hepatitis
9 C. *Gut* 52: 1638-1643.
- 10 Barreiro P, Martin-Carbonero L, Nunez M, Rivas P, Morente A, Simarro N, Labarga P,
11 Gonzalez-Lahoz J, Soriano V. 2006. Predictors of liver fibrosis in HIV-infected patients with
12 chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role
13 of HCV genotype 3. *Clin Infect Dis* 42: 1032-1039.
- 14 Bedossa P, Poynard T. 1996. An algorithm for the grading of activity in chronic hepatitis C.
15 The METAVIR Cooperative Study Group. *Hepatology* 24: 289-293.
- 16 Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, Borovicka J, Heim M,
17 Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F. 2009. Genotype 3 is associated
18 with accelerated fibrosis progression in chronic hepatitis C. *J Hepatol* 51: 655-666.
- 19 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E,
20 Pagliaro L, Colombo M, Rodes J. 2001. Clinical management of hepatocellular carcinoma.

- 1
2
3 1 Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of
4 the Liver. *J Hepatol* 35: 421-430.
5
6
7
8
9
10 3 Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. 2006.
11
12 4 Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin
13 resistance and hepatic steatosis. *Hepatology* 44: 1648-1655.
14
15
16
17
18
19 6 Campbell JV, Hagan H, Latka MH, Garfein RS, Golub ET, Coady MH, Thomas DL,
20
21 7 Strathdee SA. 2006. High prevalence of alcohol use among hepatitis C virus antibody
22 positive injection drug users in three US cities. *Drug Alcohol Depend* 81: 259-265.
23
24
25
26
27
28 9 Carpenter JR, Kenward MG, White IR. 2007. Sensitivity analysis after multiple imputation
29 under missing at random: a weighting approach. *Stat Methods Med Res* 16: 259-275.
30
31
32
33
34
35 11 Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, Dhumeaux
36 D. 2003. Worsening of steatosis is an independent factor of fibrosis progression in untreated
37 patients with chronic hepatitis C and paired liver biopsies. *Gut* 52: 288-292.
38
39
40
41
42
43
44 14 Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux
45 D. 2004. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic
46 hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. *Gut* 53:
47 420-424.
48
49
50
51
52
53
54
55
56 18 Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM. 2009. The impact of hepatic steatosis
57 on the natural history of chronic hepatitis C infection. *J Viral Hepat* 16: 492-499.
58
59
60

- 1
2
3 1 Cua IH, Hui JM, Kench JG, George J. 2008. Genotype-specific interactions of insulin
4 resistance, steatosis, and fibrosis in chronic hepatitis C. *Hepatology* 48: 723-731.
5
6
7
8
9
10 3 Delarocque-Astagneau E, Meffre C, Dubois C, Pioche C, Le Strat Y, Roudot-Thoraval F,
11 Hillon P, Silvain C, Dhumeaux D, Desenclos JC. 2009. The impact of the prevention
12 programme of hepatitis C over more than a decade: the French experience. *J Viral Hepat*
13 [Epub ahead of print].
14
15
16
17
18
19
20
21 7 Delarocque-Astagneau E, Roudot-Thoraval F, Campese C, Desenclos JC, The Hepatitis
22 CSSS. 2005. Past excessive alcohol consumption: a major determinant of severe liver disease
23 among newly referred hepatitis C virus infected patients in hepatology reference centers,
24 France, 2001. *Ann Epidemiol* 15: 551-557.
25
26
27
28
29
30
31
32
33 11 Dhumeaux D, Marcellin P, Lerebours E. 2003. Treatment of hepatitis C. The 2002 French
34 consensus. *Gut* 52: 1784-1787.
35
36
37
38
39
40 13 Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. 2005. Impact of steatosis on
41 progression of fibrosis in patients with mild hepatitis C. *Hepatology* 41: 82-87.
42
43
44
45
46
47 15 Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM,
48 Dhumeaux D, Lotersztajn S, Mallat A. 2005. Daily cannabis smoking as a risk factor for
49 progression of fibrosis in chronic hepatitis C. *Hepatology* 42: 63-71.
50
51
52
53
54
55
56 18 Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA. 2004.
57 Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a
58 retrospective study on a large cohort of patients in the United States. *J Hepatol* 40: 147-154.
59
60

- 1
2
3 1 Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, George J. 2002.
4
5 2 Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. *J*
6
7
8 3 *Gastroenterol Hepatol* 17: 873-881.
9
10
11
12 4 Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. 2003.
13
14 5 Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis
15
16 6 progression [corrected]. *Gastroenterology* 125: 1695-1704.
17
18
19
20
21 7 Jauffret-Roustide M, Le SY, Couturier E, Thierry D, Rondy M, Quaglia M, Razafandratsima
22
23 8 N, Emmanuelli J, Guibert G, Barin F, Desenclos JC. 2009. A national cross-sectional study
24
25 9 among drug-users in France: epidemiology of HCV and highlight on practical and statistical
26
27 10 aspects of the design. *BMC Infect Dis* 9: 113.
28
29
30
31
32
33 11 Larsen C, Pialoux G, Salmon D, Antona D, Le SY, Piroth L, Pol S, Rosenthal E, Neau D,
34
35 12 Semaille C, Delarocque AE. 2008. Prevalence of hepatitis C and hepatitis B infection in the
36
37 13 HIV-infected population of France, 2004. *Euro Surveill* 13.
38
39
40
41
42 14 Lefrere JJ, Roudot-Thoraval F, Lunel F, Alain S, Chaix ML, Dussaix E, Gassin M, Izopet J,
43
44 15 Pawlotsky JM, Payan C, Stoll-Keller F, Thibault V, Trabaud MA, Bettinger D, Bogard M,
45
46 16 Branger M, Buffet-Janvresse C, Charrois A, Defer C, Laffont C, Lerable J, Levayer T,
47
48 17 Martinot-Peignoux M, Mercier B, Rosenberg AR. 2004. Expertise of French laboratories in
49
50 18 detection, genotyping, and quantification of hepatitis C virus RNA in serum. *J Clin Microbiol*
51
52 19 42: 2027-2030.
53
54
55
56
57
58 20 Little RJ & Rubin DB, editors. 2002. *Statistical analysis with missing data*, 2nd ed. Hoboken,
59
60 21 NJ: John Wiley & Sons, Inc.

- 1
2
3 1 Mallat A, Hezode C, Lotersztajn S. 2008. Environmental factors as disease accelerators
4
5
6 2 during chronic hepatitis C. *J Hepatol* 48: 657-665.
7
8
9
10 3 Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, Antona D,
11
12 4 Bovet M, Mechain M, Asselah T, Desenclos JC, Jouglu E. 2008. Mortality related to chronic
13
14 5 hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and
15
16 6 alcohol consumption. *J Hepatol* 48: 200-207.
17
18
19
20
21 7 Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, Poynard T. 2006.
22
23 8 Natural history and predictors of disease severity in chronic hepatitis C. *J Hepatol* 44: S19-
24
25 9 S24.
26
27
28
29
30
31 10 Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM,
32
33 11 Warszawski J, Steinmetz J, Coste D, Meyer JF, Leiser S, Giordanella JP, Gueguen R,
34
35 12 Desenclos JC. 2010. Prevalence of hepatitis B and hepatitis C virus infections in France in
36
37 13 2004: Social factors are important predictors after adjusting for known risk factors. *J Med*
38
39 14 *Virol* 82: 546-555.
40
41
42
43
44
45 15 Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R,
46
47 16 Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D,
48
49 17 Bedossa P, Marcellin P. 2008. Insulin resistance in chronic hepatitis C: association with
50
51 18 genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. *Gastroenterology* 134: 416-
52
53 19 423.
54
55
56
57
58 20 Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet
59
60 21 P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C,

- 1
2
3 1 Coude M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I,
4
5 2 Halfon P, Bourliere M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V,
6
7 3 Thieffn G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M,
8
9 4 Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML,
10
11 5 Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrere JJ,
12
13 6 Lunel-Fabiani F. 2005. Changing of hepatitis C virus genotype patterns in France at the
14
15 7 beginning of the third millenium: The GEMHEP GenoCII Study. *J Viral Hepat* 12: 405-413.
16
17
18
19
20
21
22 8 Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, Liang TJ, Hoofnagle
23
24 9 JH, Ghany MG. 2006. Steatosis and progression of fibrosis in untreated patients with chronic
25
26 10 hepatitis C infection. *Hepatology* 43: 780-787.
27
28
29
30
31 11 Petta S, Camma C, Di M, V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F,
32
33 12 Tarantino G, Marchesini G, Craxi A. 2008. Insulin resistance and diabetes increase fibrosis in
34
35 13 the liver of patients with genotype 1 HCV infection. *Am J Gastroenterol* 103: 1136-1144.
36
37
38
39
40 14 Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau
41
42 15 M, Ratzu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P. 2003. A comparison of
43
44 16 fibrosis progression in chronic liver diseases. *J Hepatol* 38: 257-265.
45
46
47
48
49 17 Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M. 2009. Little evidence that
50
51 18 hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess
52
53 19 alcohol intake: the Swiss Hepatitis C Cohort Study. *J Viral Hepat* 16: 644-649.
54
55
56
57
58 20 Rothman, K. & Greenland, S. (1998). Types of epidemiologic studies. In: *Modern*
59
60 21 *Epidemiology*, pp. 67-78. Philadelphia: Lippincott Raven.

- 1
2
3 1 Royston P. 2007. Multiple imputation of missing values: further update of ice, with an
4
5 2 emphasis on interval censoring. *Stata Journal* 7: 445-464.
6
7
8
9
10 3 Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola
11
12 4 L, Smedile A, Negro F. 2004. Steatosis affects chronic hepatitis C progression in a genotype
13
14 5 specific way. *Gut* 53: 406-412.
15
16
17
18
19 6 Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. 2004. Progression of hepatic
20
21 7 fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. *Gut* 53: 451-455.
22
23
24
25
26 8 Schuppan D, Afdhal NH. 2008. Liver cirrhosis. *Lancet* 371: 838-851.
27
28
29
30 9 Thein HH, Yi Q, Dore GJ, Krahn MD. 2008. Natural history of hepatitis C virus infection in
31
32 10 HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral
33
34 11 therapy: a meta-analysis. *AIDS* 22: 1979-1991.
35
36
37
38
39 12 Tolstrup JS, Gronbaek M, Tybjaerg-Hansen A, Nordestgaard BG. 2009. Alcohol intake,
40
41 13 alcohol dehydrogenase genotypes, and liver damage and disease in the Danish general
42
43 14 population. *Am J Gastroenterol* 104: 2182-2188.
44
45
46
47
48
49 15 Westin J, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, Dhillon AP, Norkrans G,
50
51 16 Wejstal R. 2002. Moderate alcohol intake increases fibrosis progression in untreated patients
52
53 17 with hepatitis C virus infection. *J Viral Hepat* 9: 235-241.
54
55
56
57
58 19
59
60

Table I: Main characteristics of HCV RNA positive drug users at first referral to hepatology reference centres in France, 2001-2007.

Characteristic	All patients (n = 4236)	HCV genotype 3 (n = 1077)	other HCV genotypes (n = 1986)
Sex ratio (female/male)	1 / 3	1 / 3	1 / 3
Age, years	39 (10)	39 (11)	40 (10)
Duration of HCV infection ^a , years,	18 (12)	18 (12)	19 (12)
ALT level ^b , xULN	1.5 (1.5)	2.0 (1.9)	1.5 (1.2)
History of excessive alcohol intake ^c			
Missing	467 (11.0)	119 (11.1)	212 (10.7)
No	1952 (46.1)	499 (46.3)	908 (45.7)
Yes	1817 (42.9)	459 (42.6)	866 (43.6)
HIV serostatus			
Missing	702 (16.6)	162 (15.0)	289 (14.6)
Negative	3284 (77.5)	868 (80.6)	1 557 (78.4)
Positive	250 (5.9)	47 (4.4)	140 (7.0)
HBsAg serostatus			
Missing	685 (16.2)	150 (13.9)	285 (14.3)
Negative	3466 (81.8)	906 (84.1)	1 660 (83.6)
Positive	85 (2.0)	21 (2.0)	41 (2.1)
HCV genotype			
Missing	1173 (27.7)		
1 non a, b	407 (9.6)		
1a	694 (16.4)		
1b	439 (10.3)		
2	117 (2.8)		
3 non a	317 (7.5)		
3a	760 (17.9)		
4	325 (7.7)		
5	4 (0.1)		
Clinical stage at 1 st referral			
Missing	171 (4.1)	31 (2.9)	58 (2.9)
Normal ALT values	713 (16.8)	116 (10.8)	356 (17.9)
Chronic hepatitis	3000 (70.8)	815 (75.6)	1419 (71.4)
Cirrhosis ^d	301 (7.1)	97 (9.0)	132 (6.7)
Hepatocellular carcinoma	10 (0.2)	3 (0.3)	4 (0.2)
Acute hepatitis	41 (1.0)	15 (1.4)	17 (0.9)
Liver biopsy at 1 st referral	1765 (41.7)	405 (37.6)	992 (49.9)
Fibrosis Metavir [Bedossa and Poynard, 1996] score at liver biopsy	1725	396	976
F0	138 (8.0)	25 (6.3)	81 (8.3)
F1	735 (42.6)	136 (34.3)	455 (46.6)
F2	480 (27.8)	112 (28.3)	264 (27.1)
F3	195 (11.3)	62 (15.7)	94 (9.6)
F4	177 (10.3)	61 (15.4)	82 (8.4)

1
2
3 1 Note. Data are no. (%) of patients or median values (interquartile range), unless otherwise indicated. HCV, hepatitis
4 2 C virus; IQR, interquartile range; SD, standard deviation; ALT, alanine aminotransferase; ULN, upper limit of
5 3 normal; HIV, human immunodeficiency virus; HBsAg, hepatitis B surface antigen;
6 4 ^a available for 3626 (85.6%) HCV RNA+ drug users, for 932 (86.5%) infected with genotype 3, for 1673 (84.2%)
7 5 infected with other genotype;
8 6 ^b available for 3938 (93.0%) HCV RNA+ drug users, for 1023 (95.0%) infected with genotype 3, for 1906 (96.0%)
9 7 infected with other genotype;
10 8 ^c >210 g/week for women and >280 g/week for men (g= gram of ethanol)
11 9 ^d including decompensated cirrhosis
12 10
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Table II: Factors associated with severe liver disease at clinical evaluation in HCV RNA positive drug users at first referral to hepatology reference centres in France, 2001-2007

Factors	Patients (n = 4065)	% SLD	Univariate Analysis	
			OR (95% CI)	p
Period of inclusion				
2001-2003	2211	6.8	1	
2004-2007	1854	8.7	1.3 (1.0-1.6)	0.02
Sex				
Female	929	4.0	1	
Male	3136	8.7	2.3 (1.6-3.3)	<0.001
Age				
≤ 40 years	2302	3.7	1	
> 40 years	1763	12.8	3.8 (2.9-4.9)	<0.001
Time between 1 st HCV+ test and referral				
< 1 year	1683	6.8	1	
≥ 1 year	1987	7.7	1.1 (0.9-1.5)	0.3
Missing	395	10.6		
Duration of HCV infection at referral ^a				
< 18 years	1636	3.0	1	
≥ 18 years	1843	12.5	4.7 (3.4-6.5)	<0.001
Missing	586	7.7		
History of excessive alcohol intake ^b				
No	1881	4.1	1	
Yes	1740	12.5	3.3 (2.5-4.3)	<0.001
Missing	444	3.6		
HBsAg				
Negative	3366	7.8	1	
Positive	83	13.2	1.8 (0.9-3.4)	0.07
Missing	616	6.0		
HIV				
Negative	3180	7.7	1	
Positive	240	12.9	1.8 (1.2-2.7)	0.004
Missing	645	5.6		
HCV genotype 3				
No	1928	7.0	1	
Yes	1046	9.6	1.4 (1.1-1.8)	0.02
Missing	1091	6.9		

Note. SLD, severe liver disease (cirrhosis, hepatocellular carcinoma); aOR, odds ratio; CI, confidence interval; HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus;

^a Time from suspected year of infection to year of referral to the reference centre. Suspected year of HCV infection is defined as year of the last HCV negative test performed during the drug-use period or year of first drug injection

^b >210g/week for women and >280g/week for men (g = gram of ethanol)

Table III: Factors independently associated with severe liver disease at clinical evaluation in HCV RNA positive drug users at first referral to hepatology reference centres in France, 2001-2007

Factors	Multivariate analysis			
	Complete case (n = 2294)		Multiple imputation (n = 4065)	
	aOR (95% CI)	p	aOR (95% CI)	p
Sex				
Female	1		1	
Male	2.0 (1.2-3.1).	0.005	2.0 (1.4-2.8)	<0.001
Age				
≤ 40 years	1		1	
> 40 years	2.4 (1.6-3.6)	<0.001	2.1 (1.6-2.9)	<0.001
Duration of HCV infection at referral^a				
< 18 years	1		1	
≥ 18 years	2.9 (1.8-4.6)	<0.001	2.9 (2.0-4.3)	<0.001
History of excessive alcohol intake^b				
No	1		1	
Yes	2.6 (1.8-3.6)	<0.001	2.8 (2.1-3.7)	<0.001
HCV genotype 3				
No	1		1	
Yes	1.4 (1.0-1.9)	0.05	1.6 (1.2-2.1)	0.003
HIV serostatus^c				
Negative	-	-	1	
Positive	-	-	1.8 (1.2-2.8)	0.005

Note. severe liver disease (cirrhosis, hepatocellular carcinoma); aOR, adjusted odds ratio; CI, confidence interval; HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus;

^a Time from suspected year of infection to year of referral to the reference centre. Suspected year of HCV infection is defined as year of the last HCV negative test performed during the drug-use period or year of first drug injection

^b >210g/week for women and >280g/week for men (g = gram of ethanol)

^c HIV serostatus did not remain significant in the complete case analysis